Sage Therapeutics (SAGE) saw its stock price soar last year when the company’s investigational treatment for postpartum depression succeeded in a pair of late-stage clinical trials. On Friday, the Food and Drug Administration and its independent experts get their chance to weigh in on whether the intravenous treatment deserves approval.
The treatment, brexanolone, is widely expected to win over the FDA’s advisers and get approved later this year. But Sage’s therapy is not without outstanding questions. Here’s a look at the unknowns tied to Sage and its seemingly promising drug.